Clinical trials for Bladder / Urinary Tract / Urethral cancer

129 currently recruiting clinical trials
Early Access Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Early Access Bladder / Urinary Tract / Urethral cancer
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06960577
Required histologic types
Invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
1 recruiting site
AstraZeneca
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07419295
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06510374
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
10 recruiting sites
Ferring Pharmaceuticals
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06545955
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Surgery Immunotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Ferring Pharmaceuticals
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06919965
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Immunotherapy
7 recruiting sites
Janssen
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07106762 #2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT06022289
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Tianjin Medical University Second Hospital